评价原发性肝癌消融术后复发的实验室及影像学指标研究进展
摘要
近年来,采用微创介入如射频消融治疗、微波消融治疗、氩氦刀冷冻消融治疗等治疗肝癌,越来越多的被肝癌患者接受,与外科切除并列作为早期肝癌的首选治疗。但介入治疗普及的同时,其术后复发的问题也引起临床的重视,它影响着微创介入的疗效及患者的生存质量。本文对原发性肝癌消融术后复发的实验室和影像学指标作一综述。
引文
[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65:87-108.
[2]Xie YH.Hepatitis B virus-associated hepatocellular carcinoma[J].Adv Exp Med Biol,2017,1018:11-21.
[3]Wallace MC,Preen D,Jeffrey GP,et al.The evolving epidemiology of hepatocellular carcinoma:a global perspective[J].Expert Rev Gastroenterol Hepatol,2015,9:765-779.
[4]El-Serag HB,Rudolph KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology,2007,132:2557-2576.
[5]Hocquelet A,Balageas P,Laurent C,et al.Radiofrequency ablation versus surgical resection for hepatocellular carcinoma within the Milan criteria:a study of 281 western patients[J].Int J Hyperthermia,2015,31:749-757.
[6]Chen K,Zhan MX,Hu BS,et al.Combination of the neutrophil to lymphocyte ratio and the platelet lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma[J].Oncol Lett,2018,15:315-323.
[7]Zheng J,Cai J,Li H,et al.Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments:a Meta-analysis and systematic review[J].Cell Physiol Biochem,2018,44:967-981.
[8]Casadei Gardini A,Scarpi E,Faloppi L,et al.Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib[J].Oncotarget,2016,7:67142-67149.
[9]Jiang N,Deng JY,Liu Y,et al.The role of preoperative neutrophillymphocyte and platelet-lymphocyte ratio in patients after radical resection for gastric cancer[J].Biomarkers,2014,19:444-451.
[10]Chu MO,Shen CH,Chang TS,et al.Pretreatment inflammationbased markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation[J].Sci Rep,2018,8:16611.
[11]Chung HA,Kim JH,Hwang Y,et al.Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation[J].Saudi J Gastroenterol,2016,22:57-63.
[12]Rahbari NN,Mehrabi A,Mollberg NM,et al.Hepatocellular carcinoma:current management and perspectives for the future[J].Ann Surg,2011,253:453-469.
[13]Riaz A,Ryu RK,Kulik LM,et al.Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma:oncologic marker of radiologic response,progression and survival[J].J Clin Oncol,2009,27:5734-5742.
[14]Hu J,Wang N,Yang Y,et al.Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma[J].BMC Gastroenterol,2018,18:186.
[15]Yu SJ,Kwon JH,Kim W,et al.Initial alpha-fetoprotein response predicts prognosis in hepatitis B-related solitary HCC patients after radiofrequency ablation[J].J Clin Gastroenterol,2018,52:e18-e26.
[16]European Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67:370-398.
[17]Huang G,Li PP,Lau WY,et al.Antiviral therapy reduces hepatocellular c-arcinoma recurrence in patients with low HBV-DNA levels:a randomized controlled trial[J].Ann Surg,2018,268:943-954.
[18]Liu WR,Tian MX,Jin L,et al.High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads[J].Ann Surg Oncol,2015,22:843-850.
[19]Zhou HB,Li QM,Zhong ZR,et al.Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load[J].Am J Cancer Res,2015,5:756-771.
[20]Zhang L,Xie XY,Ge NL,et al.Hepatitis B surface antigen predicts recu-rrence after radiofrequency ablation in patients with low hepatitis B virus loads[J].Medicine(Baltimore),2017,96:e9377.
[21]Takahashi M,Maruyama H,Ishibashi H,et al.Contrast-enhanced ultrasound with perflubutane microbubble agent:evaluation of differentiation of hepatocellular carcinoma[J].AJR Am J Roentgenol,2011,196:W123-W131.
[22]Maruyama H,Takahashi M,Shimada T,et al.Pretreatment microbubble-induced enhancement in hepatocellular carcinoma predicts intrahepatic distant recurrence after radiofrequency ablation[J].AJR Am J Roentgenol,2013,200:570-577.
[23]Jin YJ,Nah SY,Lee JW,et al.Utility of adding primovist magnetic reasonance imaging to analysis of hepatocellular carcinoma by liver dynamic computed tomography[J].Clin Gastroenterol Hepatol,2013,11:187-192.
[24]Kim HD,Lim YS,Han S,et al.Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival[J].Gastroenterology,2015,148:1371-1382.
[25]Imai Y,Katayama K,Hori M,et al.Prospective comparison of GdEOB-DTPA-enhanced MRI with dynamic CT for detecting recurrence of HCC after radiofrequency ablation[J].Liver Cancer,2017,6:349-359.
[26]Iwamoto T,Imai Y,Igura T,et al.Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetri-amine pentaacetic acid-enhanced MRI as a risk factor of intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma[J].Dig Dis,2017,35:574-582.
[27]Toyoda H,Kumada T,Tada T,et al.Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC[J].Hepatol Int,2015,9:84-92.
[28]Tummers QR,Verbeek FP,Prevoo HA,et al.First experience on laparoscopic near-infrared fluorescence imaging of hepatic uveal melanoma metastases using indocyanine green[J].Surg Innov,2015,22:20-25.
[2]Xie YH.Hepatitis B virus-associated hepatocellular carcinoma[J].Adv Exp Med Biol,2017,1018:11-21.
[3]Wallace MC,Preen D,Jeffrey GP,et al.The evolving epidemiology of hepatocellular carcinoma:a global perspective[J].Expert Rev Gastroenterol Hepatol,2015,9:765-779.
[4]El-Serag HB,Rudolph KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology,2007,132:2557-2576.
[5]Hocquelet A,Balageas P,Laurent C,et al.Radiofrequency ablation versus surgical resection for hepatocellular carcinoma within the Milan criteria:a study of 281 western patients[J].Int J Hyperthermia,2015,31:749-757.
[6]Chen K,Zhan MX,Hu BS,et al.Combination of the neutrophil to lymphocyte ratio and the platelet lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma[J].Oncol Lett,2018,15:315-323.
[7]Zheng J,Cai J,Li H,et al.Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments:a Meta-analysis and systematic review[J].Cell Physiol Biochem,2018,44:967-981.
[8]Casadei Gardini A,Scarpi E,Faloppi L,et al.Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib[J].Oncotarget,2016,7:67142-67149.
[9]Jiang N,Deng JY,Liu Y,et al.The role of preoperative neutrophillymphocyte and platelet-lymphocyte ratio in patients after radical resection for gastric cancer[J].Biomarkers,2014,19:444-451.
[10]Chu MO,Shen CH,Chang TS,et al.Pretreatment inflammationbased markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation[J].Sci Rep,2018,8:16611.
[11]Chung HA,Kim JH,Hwang Y,et al.Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation[J].Saudi J Gastroenterol,2016,22:57-63.
[12]Rahbari NN,Mehrabi A,Mollberg NM,et al.Hepatocellular carcinoma:current management and perspectives for the future[J].Ann Surg,2011,253:453-469.
[13]Riaz A,Ryu RK,Kulik LM,et al.Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma:oncologic marker of radiologic response,progression and survival[J].J Clin Oncol,2009,27:5734-5742.
[14]Hu J,Wang N,Yang Y,et al.Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma[J].BMC Gastroenterol,2018,18:186.
[15]Yu SJ,Kwon JH,Kim W,et al.Initial alpha-fetoprotein response predicts prognosis in hepatitis B-related solitary HCC patients after radiofrequency ablation[J].J Clin Gastroenterol,2018,52:e18-e26.
[16]European Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67:370-398.
[17]Huang G,Li PP,Lau WY,et al.Antiviral therapy reduces hepatocellular c-arcinoma recurrence in patients with low HBV-DNA levels:a randomized controlled trial[J].Ann Surg,2018,268:943-954.
[18]Liu WR,Tian MX,Jin L,et al.High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads[J].Ann Surg Oncol,2015,22:843-850.
[19]Zhou HB,Li QM,Zhong ZR,et al.Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load[J].Am J Cancer Res,2015,5:756-771.
[20]Zhang L,Xie XY,Ge NL,et al.Hepatitis B surface antigen predicts recu-rrence after radiofrequency ablation in patients with low hepatitis B virus loads[J].Medicine(Baltimore),2017,96:e9377.
[21]Takahashi M,Maruyama H,Ishibashi H,et al.Contrast-enhanced ultrasound with perflubutane microbubble agent:evaluation of differentiation of hepatocellular carcinoma[J].AJR Am J Roentgenol,2011,196:W123-W131.
[22]Maruyama H,Takahashi M,Shimada T,et al.Pretreatment microbubble-induced enhancement in hepatocellular carcinoma predicts intrahepatic distant recurrence after radiofrequency ablation[J].AJR Am J Roentgenol,2013,200:570-577.
[23]Jin YJ,Nah SY,Lee JW,et al.Utility of adding primovist magnetic reasonance imaging to analysis of hepatocellular carcinoma by liver dynamic computed tomography[J].Clin Gastroenterol Hepatol,2013,11:187-192.
[24]Kim HD,Lim YS,Han S,et al.Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival[J].Gastroenterology,2015,148:1371-1382.
[25]Imai Y,Katayama K,Hori M,et al.Prospective comparison of GdEOB-DTPA-enhanced MRI with dynamic CT for detecting recurrence of HCC after radiofrequency ablation[J].Liver Cancer,2017,6:349-359.
[26]Iwamoto T,Imai Y,Igura T,et al.Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetri-amine pentaacetic acid-enhanced MRI as a risk factor of intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma[J].Dig Dis,2017,35:574-582.
[27]Toyoda H,Kumada T,Tada T,et al.Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC[J].Hepatol Int,2015,9:84-92.
[28]Tummers QR,Verbeek FP,Prevoo HA,et al.First experience on laparoscopic near-infrared fluorescence imaging of hepatic uveal melanoma metastases using indocyanine green[J].Surg Innov,2015,22:20-25.